Breast Cancer Drug Toremifene Emerges as Surprising Ebola Blocker Especially for the Bundibugyo Strain
Nikhil Prasad Fact checked by:Thailand Medical News Team May 24, 2026 1 hour, 14 minutes ago
Medical News: A decades old breast cancer drug is drawing renewed scientific attention after multiple studies showed that it can stop the Ebola virus from entering human cells and dramatically improve survival in infected animals.
Researchers now believe the drug, called toremifene, could become part of a powerful antiviral strategy against some of the world’s deadliest filoviruses.
Scientists discover that breast cancer drug toremifene can destabilize Ebola virus proteins and block deadly infections
Originally developed as a selective estrogen receptor modulator for hormone sensitive breast cancer, toremifene is now being investigated for an entirely different purpose.
Scientists discovered that its antiviral activity has nothing to do with hormones or estrogen receptors. Instead, the drug appears to physically destabilize the Ebola virus itself.
How Toremifene Stops Ebola Infection
The Ebola virus infects cells through a surface structure known as the glycoprotein or GP. This protein acts like a molecular grappling hook, helping the virus attach to host cells and fuse with cellular membranes after entering endosomes. Once fusion occurs, the virus releases its genetic material into the cell and rapidly multiplies.
Researchers using high resolution structural imaging discovered that toremifene binds directly to a hidden cavity within the Ebola glycoprotein complex. The binding site sits between GP1 and GP2, two critical viral subunits involved in cell entry.
The drug’s attachment destabilizes the glycoprotein structure and triggers premature release of the GP2 fusion machinery before the virus can successfully merge with the host membrane. As a result, Ebola becomes trapped inside cellular compartments and cannot complete infection.
Scientists observed that the drug lowered the glycoprotein melting temperature by as much as 14 degrees Celsius, showing just how severely the viral structure was disrupted. This mechanism is considered highly significant because it targets one of the virus’s most vulnerable steps.
Mouse Studies Produced Remarkable Survival Results
In laboratory animal experiments, toremifene produced surprisingly strong protective effects. Studies showed that 50 percent of Ebola infected mice treated with the drug survived at least 28 days, while untreated control animals uniformly died within days. Earlier experiments also demonstrated major reductions in viral replication after treatment.
Scientists screened thousands of approved drugs in an effort to rapidly identify therapies that could be repurposed during Ebola outbreaks. Toremifene quickly stood out because it already had an established safety profile from cancer treatment use.
This
Medical News report notes that researchers believe drug repurposing may provide one of the fastest ways to respond to emerging viral threats without waiting years for entirely new medications to be developed.
g>Drug Combinations May Work Even Better
One of the most exciting developments involves combining toremifene with other approved drugs. Researchers found strong synergistic effects when the drug was paired with antifungal medication posaconazole and antibiotics such as clarithromycin. Another promising triple combination involved mefloquine, an antimalarial drug.
These combinations were able to block Ebola infection far more effectively than individual drugs alone. Scientists said the synergy could potentially reduce the amount of toremifene needed, making treatment safer and more clinically practical.
The combinations appear to interfere with several different stages of Ebola entry and intracellular trafficking simultaneously.
While toremifene destabilizes the viral glycoprotein, companion drugs may disrupt lysosomal calcium signaling, endosomal processing, or membrane transport pathways that Ebola depends upon.
Potential Against Multiple Deadly Filoviruses
Another important discovery is that the glycoprotein binding region targeted by toremifene is highly conserved across several filoviruses. This means the drug may not only work against the classic Zaire Ebola strain but also against Bundibugyo and Tai Forest viruses.
Researchers are especially interested in whether future optimized derivatives of toremifene could become broad spectrum antivirals against emerging hemorrhagic fever viruses.
Although monoclonal antibody therapies now exist for the Ziare strain of Ebola, scientists say orally available small molecule drugs remain urgently needed because they are easier to stockpile, transport, and administer during outbreaks in remote regions.
The growing body of evidence surrounding toremifene has transformed what was once considered an unlikely candidate into one of the more intriguing repurposed antiviral agents studied against Ebola.
Scientists caution that human clinical trials are still needed before widespread therapeutic use can be recommended.
However, the drug’s unique ability to directly destabilize Ebola’s fusion machinery, combined with encouraging survival data and potent drug synergy findings, has positioned it as a promising candidate in future outbreak preparedness strategies. Researchers are now exploring whether next generation compounds based on the same mechanism could deliver even greater potency with fewer side effects, potentially opening an entirely new front in the battle against lethal filoviruses.
References:
https://www.nature.com/articles/nature18615
https://www.science.org/doi/10.1126/scitranslmed.3005471
https://linkinghub.elsevier.com/retrieve/pii/S0166354216306167
https://www.diamond.ac.uk/Home/News/LatestNews/2016/29-06-16.html
https://www.uvahealth.com/news/drugs-show-promise-for-stopping-deadly-ebola
For the latest Ebola news, keep on logging to Thailand Medical News.
Read Also:
https://www.thailandmedical.news/articles/ebola
Medical Disclaimer: All content published by Thailand Medical News is based on scientific research and is intended for informational and educational purposes only. It is not medical advice, diagnosis, or treatment. Readers must not attempt to use, apply, or experiment with any protocols, compounds, or therapies mentioned without first consulting a qualified and licensed medical doctor. Many findings discussed are experimental or preliminary, and only a licensed healthcare professional can determine what is safe and appropriate for an individual’s specific medical condition.
Share
Tweet
Share
